Louis Sullivan - EMERGENT BIOSOLUT Independent Director
| ER4 Stock | EUR 9.49 0.01 0.11% |
Director
The Hon. Dr. Louis W. Sullivan, M.D., is Independent Director of the Company. Dr. Sullivan has served as president emeritus of Morehouse School of Medicine since July 2002. Dr. Sullivan served as president of Morehouse School of Medicine from 1981 to 1989 and from 1993 to 2002. From 1989 to 1993, Dr. Sullivan was Secretary of the Department of Health and Human Services. Dr. Sullivan serves on the board of directors of United Therapeutics Corporationrationration, a publiclytraded biotechnology company. He served as a director for Henry Schein, Inc. a publiclytraded biotechnology company, from 2004 to June 2016. He was a founder and chairman of Medical Education for South African Blacks, Inc., a trustee of Africare, a director of the National Center on Addiction and Substance Abuse at Columbia University and chairman of the board of trustees of the National Health Museum, a nonprofit institution developing a museum of health sciences since 2011.
| Age | 85 |
| Tenure | 13 years |
| Professional Marks | Ph.D |
Similar Executives
| Found 7 records | DIRECTOR Age | ||
| Harriett Taggart | The Hanover Insurance | 71 | |
| Jane Carlin | The Hanover Insurance | 63 | |
| Kevin Bradicich | The Hanover Insurance | 61 | |
| Kathleen Lane | The Hanover Insurance | 61 | |
| Daniel Henry | The Hanover Insurance | 69 | |
| Wendell Knox | The Hanover Insurance | 71 | |
| Joseph Ramrath | The Hanover Insurance | 62 | |
EMERGENT BIOSOLUT Leadership Team
Elected by the shareholders, the EMERGENT BIOSOLUT's board of directors comprises two types of representatives: EMERGENT BIOSOLUT inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EMERGENT. The board's role is to monitor EMERGENT BIOSOLUT's management team and ensure that shareholders' interests are well served. EMERGENT BIOSOLUT's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EMERGENT BIOSOLUT's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer | ||
| Sean Kirk, Executive Vice President Manufacturing and Technical Operations | ||
| Katherine Strei, Executive Vice President, Human Resources and Communications, Chief Human Resources Officer | ||
| Fuad ElHibri, Executive Chairman of the Board | ||
| Sue Bailey, Independent Director | ||
| Jerome Hauer, Independent Director | ||
| Marvin White, Director | ||
| Kathryn Zoon, Independent Director | ||
| Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary | ||
| Seamus Mulligan, Director | ||
| George Joulwan, Independent Director | ||
| Adam Havey, Executive Vice President and Presidentident - BioDefense Division | ||
| Louis Sullivan, Independent Director | ||
| Ronald Richard, Lead Independent Director | ||
| Zsolt Harsanyi, Independent Director | ||
| Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer |
EMERGENT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EMERGENT BIOSOLUT a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 1.34 B | |||
| Price To Book | 0.43 X | |||
| Price To Sales | 0.42 X | |||
| Revenue | 1.12 B | |||
| EBITDA | (41.1 M) | |||
| Net Income | (223.8 M) | |||
| Total Debt | 448.5 M | |||
| Cash Flow From Operations | (34.1 M) | |||
| Number Of Employees | 18 | |||
| Market Capitalization | 1.91 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in EMERGENT Stock
EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.